Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
GI Cancers
First-in-Class Stem-Cell Inhibitor Active in Pancreatic and Colorectal Cancers
By
Charles Bankhead
GI Cancers
May 2016, Vol 7, No 4
The first-in-class cancer stem-cell inhibitor BBI608 demonstrated activity in advanced pancreatic cancer and colorectal cancer (CRC), according to results of 2 small studies reported at the 2016 Gastrointestinal Cancers Symposium.
Read Article
Adjuvant Therapy at High-Volume Centers Improves Pancreatic Cancer Survival
By
Charles Bankhead
GI Cancers
April 2016, Vol 7, No 3
The advantages of treatment at a high-volume center extended to adjuvant therapy in patients with resected pancreatic cancer, according to a study reported by Margaret T. Mandelson, PhD, MPH, Floyd and Dolores Jones Cancer Institute, Virginia Mason Medical Center, Seattle, WA, at the 2016 Gastrointestinal Cancers Symposium.
Read Article
Checkpoint Inhibitors Active in Gastric and Esophageal Cancers
By
Charles Bankhead
GI Cancers
April 2016, Vol 7, No 3
Immune checkpoint inhibitors demonstrated varying degrees of activity in advanced gastric and esophageal cancers, according to preliminary clinical studies reported at the 2016 Gastrointestinal Cancers Symposium.
Read Article
Consuming 4 Cups of Coffee Improves Outcomes in Patients with Stage III Colon Cancer
By
Mary Mosley
GI Cancers
November 2015, Vol 6, No 10
An apple a day keeps the doctor away. And now it seems that 4 cups of coffee a day may reduce recurrence and death in patients with stage III colon cancer after surgical resection and adjuvant chemotherapy, according to a study led by Brendan J. Guercio, MD, Harvard Medical School, Boston.
Read Article
Aprepitant Improves Emesis Control in Patients with Colorectal Cancer
Colorectal Cancer
,
GI Cancers
November 2015, Vol 6, No 10
Barcelona, Spain—Controlling and minimizing nausea and vomiting enables patients with cancer to continue their chemotherapy. A clinical trial reported at the 2015 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer shows that the newly approved agent aprepitant (Emend), an oral neurokinin (NK)
1
antagonist, improved antiemetic control in patients with colorectal cancer (CRC) who were receiving oxaliplatin-based chemotherapy, according to Junichi Nishimura, MD, Assistant Professor, Osaka University, Japan.
Read Article
Systemic Therapy plus Radiofrequency: Ablation Survival Benefit in Colorectal Liver Metastases
By
Walter Alexander
GI Cancers
November 2015, Vol 6, No 10
Barcelona, Spain—The first randomized study prospectively investigating the efficacy of radiofrequency ablation (RFA) added to standard systemic treatment in patients with unresectable colorectal cancer (CRC) liver metastases revealed progression-free survival (PFS) and overall survival (OS) benefits, according to Theo J.M. Ruers, MD, PhD, Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam.
Read Article
Ramucirumab Confers Survival Benefit in Some Patients with Hepatocellular Carcinoma
By
Walter Alexander
GI Cancers
November 2015, Vol 6, No 10
Barcelona, Spain—In the REACH trial evaluating ramucirumab (Cyramza) as second-line treatment in patients with advanced hepatocellular carcinoma after first-line therapy with sorafenib (Nexavar), overall survival (OS) was improved in the subgroup population with baseline α-fetoprotein of ?400 ng/mL (Child-Pugh class A). The OS benefits in the overall population (Child-Pugh classes A and B) did not reach significance, said lead investigator Andrew X. Zhu, MD, PhD, Massachusetts General Hospital Cancer Center, Boston.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma